subject inclusion criteria in PK and stat and BE conclusion [Regulatives / Guidelines]

posted by Ramesh Ramalingam  – India, 2017-09-05 07:35  – Posting: # 17776
Views: 6,358

Dear All,

I have more doubt on subject inclusion criteria for pharmacokinetic and statistical analysis in fully replicate (Including NTI drugs) and partial replicate design BE studies. could you please suggest the subject inclusion criteria for PK and stat analysis (including who's data can be considered for BE)? Also, How many treatment periods subject should be completed in the study?



Regards,
Ramesh Ramalingam

Complete thread:

Activity
 Admin contact
20,132 posts in 4,245 threads, 1,383 registered users;
online 18 (0 registered, 18 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 17:55 CET

Be very, very careful what you put into that head,
because you will never, ever get it out.    Thomas Wolsey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5